Global Tuberculosis Drugs Market 2011-2015

TechNavio's analysts forecast the Global Tuberculosis Drugs market to grow at a CAGR of 6.75 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in the outbreak of TB-HIV co-infections. The Global Tuberculosis Drugs market has also been witnessing the trend of increased focus on TB vaccine development. However, insufficient demand in developed countries could pose a challenge to the growth of this market.

TechNavio's report, the Global Tuberculosis Drugs market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Tuberculosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Eli Lilly and Co. GlaxoSmithKline plc. Pfizer Inc. and Sanofi SA.

Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.

TechNavio's research portfolio in the Healthcare series includes reports on the Pharmaceutical Market, Medical Devices Market, Diagnostic Market, Vaccine Market, Oncology Market, CRO Market, Orthopedic Market, Hearing Aids Market, Dental Care Market, Medical Imaging Market, Endoscopy Market, Dialysis Market, Telemedicine Market, Cancer Drug Market, Glucose Monitoring Market, Infusion Pumps Market, Defibrillators Market, Neuromodulation Market, Capnography Market.

01. Executive Summary
02. Introduction
03. Market Coverage
Key Offerings
04. Market Landscape
04.1 Global Tuberculosis Drugs Market
Market Size
04.2 End-user Segmentation
Classification of Tuberculosis Drugs
04.3 Drugs Used for the Treatment of TB
First-line TB Drugs
Second-line TB Drugs
04.4 Five Force Analysis
05. Rate of Incidence and Prevalence
TB and HIV
MDR-TB and XDR-TB
Incidence Rate per 100,000 of the Population
The 22 HBCs
06. Vendor Landscape
07. Buying Criteria
08. Global Tuberculosis Drug Pipeline
Drugs in Discovery Stage of Development
Drugs in Preclinical Stage of Development
Drugs in Phase I Stage of Development
Drugs in Phase II Stage of Development
Drugs in Phase III Stage of Development
09. Global Tuberculosis Vaccine Pipeline
10. Market Growth Drivers
11. Drivers and Their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Eli Lilly and Co.
Business Overview
SWOT Analysis
15.2 Pfizer Inc.
Business Overview
SWOT Analysis
15.3 GlaxoSmithKline plc
Business Overview
SWOT Analysis
15.4 Sanofi SA
Business Overview
SWOT Analysis
16. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Tuberculosis Drugs Market 2011-2015 (US$ million)
Exhibit 2: End-user Segmentation
Exhibit 3: Classification of Tuberculosis Drugs
Exhibit 4: Incidence Rate per 100,000 of the Population
Exhibit 5: The 22 HBCs